Almond Doctor Partners with Wolters Kluwer to Enhance Clinical Decision-Making for Physicians in China

On May 18, Xingren Doctor announced at its Shanghai headquarters that it had officially signed an agreement with Wolters Kluwer.Wolters Kluwer’s clinical medical knowledge base, UpToDate Clinical Advisor, and the rational drug use information support system, MCDEX, have officially been integrated into the Xingren Doctor mobile application platform. Both parties willEngage in deep and sustained collaboration in areas such as resource integration, communication and coordination, and market promotion,Provide comprehensive career development advisory services to outstanding Chinese physicians, creating greater practical value for the healthcare industry.

Ms. Denise Basow, President and Chief Executive Officer of Wolters Kluwer’s Clinical Efficiency Division, introduced UpToDate as a clinical decision support system based on the principles of evidence-based medicine. Its content is authored by more than 6,000 renowned clinical experts worldwide, covering over 10,000 clinical topics across 22 specialties. The system synthesizes research evidence and provides graded recommendations that are directly applicable to clinical practice.UpToDateIt not only provides detailed guidance on disease diagnosis, treatment methods, and medication use, but also continuously updates topic-specific content in line with research advances, enabling users to promptly access the latest evidence-based clinical information. Currently, it is used by more than 1.1 million physicians across over 180 countries worldwide.UpToDate. UpToDate has launched a Chinese-language version tailored for China. “Wolters Kluwer Health covers all areas of medicine and life sciences, with numerous flagship brands. Through our partnership with Xingren Yisheng, we can better provide top-tier, evidence-based medical information to healthcare professionals in China,” said Ms. Denise Basow.

At the signing ceremony, Dr. Martin, CEO of Xingren Doctor, fully affirmed the clinical value of evidence-based medicine. He stated, “We are delighted to have the opportunity to partner with Wolters Kluwer to introduce UpToDate to the community of physicians in China, enhance their understanding of the value of evidence-based medicine, and directly assist doctors in making correct decisions in their clinical practice. Xingren Doctor boasts a large user base of physicians, and we have received extensive feedback from our users on how UpToDate has helped Chinese doctors make better clinical decisions and provide superior treatment plans for patients. In 2016, we look forward to deepening our collaboration with Wolters Kluwer to introduce UpToDate and MCDEX, an authoritative drug information support system with a substantial number of physician users in China.”

MCDEX Rational Drug Use NewsletterThe Clinical Decision Support System is a database query software system developed to meet the clinical information needs associated with professional practices in rational drug use. It integrates authoritative pharmaceutical and medical information from both domestic and international sources, comprehensively collecting the latest data and insights from authoritative literature on clinical and basic research in pharmacy and medicine, such as drug monographs, package inserts, and drug interactions, with timely updates. Implementation of this system can enhance the level of rational drug use in hospitals and reduce medication errors.

It is reported that Xingren Doctor is preparing to launch offline “multi-site practice studios” based on the WeWork model, making it the first company to propose the concept of “multi-site practice studios.”“Conceptual mobile healthcare platform. Unlike similar products, Xingren Doctor has always centered its services and product upgrades around the physician community, choosing to enter the market from the B-side (physicians) to achieve the goal of serving the C-side population (patients), thereby forming a sustainable new commercial closed loop. This approach maximizes physicians’ value and tangibly improves the current patient care experience in China. Xingren Doctor has garnered favor from prominent investment and financing institutions such as Sequoia Capital, Lightspeed China Partners, and Fountaine Capital, completing a RMB 200 million Series B financing round and accumulating approximately RMB 230 million in total investment.”